

25 Mar 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech's ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 March 2024, including: another big deal in radiopharmaceuticals; [*BioNTech SE*](#)'s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[AstraZeneca Pays \\$2bn To Keep Up With The Joneses](#)" - Scrip, 19 Mar, 2024.)

(Also see "[BioNTech Is Aggressively Advancing ADCs](#)" - Scrip, 20 Mar, 2024.)

(Also see "[China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes](#)" - Scrip, 19 Mar, 2024.)

(Also see "[Bangers In MASH: How Rezdiffra's Rivals Stack Up](#)" - Scrip, 15 Mar, 2024.)

(Also see "[Lilly, BMS, Microsoft On GenAI's Machine-First Approach Success, Cell Therapy Use](#),"

Regulation" - Scrip, 19 Mar, 2024.)

[Click here to explore this interactive content online](#) ✎